Immunomodulatory therapies in neutropenic infants (such as intravenous immunoglobulin—IVIG, granulocyte colony-stimulating factor—G-CSF, and granulocyte–macrophage colony-stimulating factor—GM-CSF) and inflammatory inhibitors (endotoxin inhibitors, cytokine inhibitors, nitric oxide synthetase inhibitors, and neutrophil adhesion inhibitors) are being evaluated for their possible role in the prevention of sepsis but are not yet recommended for routine use in neonates [125,126]. This evidence concerns the gene CSF3 and Sepsis.